Small Molecule Drug
Small Molecules vs. Biologics: What Every Biotech Investor Needs to Know
When you read about a biotech company’s pipeline, every drug falls into one of two fundamental categories: a small molecule or a biologic. This distinction affects how the drug is manufactured, how it is delivered to patients, how it is regulated by the FDA, how long it retains market exclusivity, and ultimately how much revenue…
What Is the Difference Between an NDA and a BLA? The Two Paths to FDA Drug Approval
When a biotech or pharmaceutical company completes its clinical trial program and is ready to ask the FDA for approval, it faces a fundamental fork in the road: file a New Drug Application (NDA) or file a Biologics License Application (BLA). The correct choice is not a matter of preference — it is determined entirely…
